Effects of Topical Cyclosporin-A in the Treatment of Alopecia Areata.
- Author:
Chan Woo LEE
1
;
Seung Joo SIM
;
Jung Joon EIM
;
Byung Gun LEE
;
Ki Hoon SONG
;
Ki Ho KIM
Author Information
1. Department of Dermatology, Dong-A University, College of Medicine, Pusan, Korea. khkim@daunet.donga.ac.kr
- Publication Type:Original Article
- Keywords:
Alopecia areata;
Topical Cyclosporin-A
- MeSH:
Alopecia Areata*;
Alopecia*;
Autoimmune Diseases;
Dermatitis, Atopic;
Ethanol;
Hair;
Hair Follicle;
Humans;
Scalp
- From:Korean Journal of Dermatology
2004;42(4):420-425
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Alopecia areata(AA) is believed to be an autoimmune disease in which a mononuclear cell infiltrate develops in and around anagen hair follicles. There is no clearly superior therapy in the treatment of AA, especially AA with atopic dermatitis and alopecia universalis. The theory of autoimmune pathogenesis of alopecia areata suggests a potential therapeutic effect of cyclosporin-A(CsA). OBJECTIVE: The purpose of this study is to evaluate the effectiveness of CsA in the treatment of AA. METHOD: 12 patients with severe or refractory AA were treated with DPCP for at least 12 months. They showed resistance to treatment using DPCP. CsA was made up as a 0.01M, 0.005M solution in an ethanol preparation. 1cc of 0.01M CsA solution was applied on the Lt. side scalp and 1cc of 0.005M CsA solution was applied on the Rt. side scalp. The drug was applied once per week. Response to treatment was evaluated as follows: complete recovery, more than a 80% extent of hair regrowth; marked recovery, hair regrowth of 60% to 80%, moderate recovery, hair regrowth of 40% to 60%; slight recovery, hair regrowth of 20% to 40%; no response, hair regrowth of 0% to 20%. RESULT: The Six patients with focal type AA showed a moderate recovery. Of the six patients with alopecia totalis, 4 patients showed a moderate recovery, two patients showed no response. CONCLUSION: Topical CsA therapy is recommended in severe and refractory AA.
